HEC-016

N/A

Report date: 2022/08/09 10:22:34

Base Information

Drug NameHEC-016

Drug Alias NameHEC-016

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionAnti-CLDN18

TargetsClaudin-18 splice variant 2

Therapy Area/IndicationsPancreatic NeoplasmsStomach NeoplasmsEsophageal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesPeople Hospital Of Luohu,Shenzhen

China Registration ClassN/A

Develop Information

Active CompaniesPeople Hospital Of Luohu,Shenzhen

Inactive CompaniesN/A

Active IndicationsPancreatic NeoplasmsStomach NeoplasmsEsophageal Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A